...
首页> 外文期刊>Vaccine >Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate.
【24h】

Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate.

机译:从百日咳博德特氏菌获得的外膜囊泡表达脂质A脱酰基酶PagL作为一种新型的脱细胞疫苗候选物。

获取原文
获取原文并翻译 | 示例

摘要

In an effort to devise a safer and effective pertussis acelullar vaccine, outer membrane vesicles (OMVs) were engineered to decrease their endotoxicity. The pagL gene from Bordetella bronchiseptica, which encodes a lipid A 3-deacylase, was expressed in Bordetella pertussis strain Tohama I. The resulting OMVs, designated OMVsBpPagL, contain tetra- instead of penta-acylated LOS, in addition to pertussis surface immunogens such as pertactin and pertussis toxin, as the wild type OMVs. The characterized pertussis OMVsBpPagL were used in murine B. pertussis intranasal (i.n.) challenge model to examine their protective capacity when delivered by i.n. routes. Immunized BALB/c mice were challenged with sublethal doses of B. pertussis. Significant differences between immunized animals and the PBS treated group were observed (p<0.001). Adequate elimination rates (p<0.005) were observed in mice immunized either with OMVsBpPagL and wild type OMVs. All OMV preparations tested were non toxic according to WHO criteria; however, OMVsBpPagL displayed almost no weight loss at 3 days post administration, indicating less toxicity when compared with wild type OMVs. Induction of IL6- and IL1-expression in lung after i.n. delivery as well as neutrophil recruitment to airways showed coincident results, with a lower induction of the proinflammatory cytokines and lower recruitment in the case of OMVsBpPagL compared to wild type OMVs. Given their lower endotoxic activity and retained protective capacity in the mouse model, OMVsBpPagL obtained from B. pertussis seem as interesting candidates to be considered for the development of novel multi-antigen vaccine.Digital Object Identifier http://dx.doi.org/10.1016/j.vaccine.2010.12.068
机译:为了设计一种更安全有效的百日咳百草枯疫苗,对外膜囊泡(OMV)进行了工程设计,以减少其内毒作用。百日咳博德特氏菌菌株Tohama I中表达了支气管败血博德特氏菌的 pag L基因,该基因编码脂质A 3-脱酰基酶。命名为OMVs BpPagL 的野生型OMV除了百日咳表面免疫原(如百日咳杆菌粘附素和百日咳毒素)外,还含有四取代的五酰化LOS。特有的百日咳OMVs BpPagL 用于小鼠B。百日咳鼻内(i.n.)攻击模型,以检查由i.n.递送时的保护能力路线。用亚致死剂量的B攻击免疫的BALB / c小鼠。百日咳。观察到免疫动物与PBS处理组之间的显着差异( p <0.001)。在用OMV BpPagL 和野生型OMV免疫的小鼠中观察到足够的消除率( p <0.005)。根据WHO标准,所有测试的OMV制剂均无毒;然而,OMVs BpPagL 在给药后3天几乎没有体重减轻,与野生型OMVs相比毒性较小。 i.n.后肺中IL6-和IL1-表达的诱导。与野生型OMV相比,递送和嗜中性白细胞向气道的募集显示出一致的结果,促炎细胞因子的诱导较低,而OMV PpPagL 的募集较低。鉴于它们在小鼠模型中较低的内毒素活性和保留的保护能力,因此从 B获得的OMVs BpPagL 。百日咳似乎是开发新型多抗原疫苗的有趣候选对象。数字对象标识符http://dx.doi.org/10.1016/j.vaccine.2010.12.068

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号